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Background: Seroepidemiological studies have reported associations between exposure to sexually transmitted
organisms and prostate cancer risk. This study sought DNA evidence of candidate organisms in archival prostate
cancer tissues with the aim of assessing if a subset of these cancers show any association with common genital
infections.
Methods: 221 archival paraffin-embedded tissue blocks representing 128 histopathologically confirmed prostate
cancers comprising 52 “aggressive” (Gleason score ≥ 7) and 76 “non-aggressive” (Gleason score ≤ 6) TURP or radical
prostatectomy specimens were examined, as well as unaffected adjacent tissue when available. Representative
tissue sections were subjected to DNA extraction, quality tested and screened by PCR for HSV-1, HSV-2, XMRV, BKV,
HPV, Chlamydia trachomatis, Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma genitalium, and Trichomonas
vaginalis.
Results: 195 of 221 DNA samples representing 49 “aggressive” and 66 “non-aggressive” prostate cancer cases were
suitable for analysis after DNA quality assessment. Overall, 12.2% (6/49) aggressive and 7.6% (5/66) non-aggressive
cases were positive for any of the candidate organisms. Mycoplasma genitalium DNA was detected in 4/66
non-aggressive, 5/49 aggressive cancers and in one cancer-unaffected adjacent tissue block of an aggressive case.
Ureaplasma urealyticum DNA was detected in 0/66 non-aggressive and 1/49 aggressive cancers and HSV DNA in
1/66 non-aggressive and 0/49 aggressive cancers. This study did not detect BKV, XMRV, T. vaginalis, U. parvum,
C. trachomatis or HPV DNA.
Conclusions: The low prevalence of detectable microbial DNA makes it unlikely that persistent infection by the
selected candidate microorganisms contribute to prostate cancer risk, regardless of tumour phenotype.
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The infection hypothesis for prostate cancer was first
proposed in the mid-twentieth century [1]. Subsequently,
many studies have sought associations between sexually
transmitted infections (STIs) and prostate cancer risk but
no clear association with a pathogen has been established.
A meta-analysis of 29 case–control studies (1966–2003)
reported associations between prostate cancer risk and
any STI (OR 1.48 95% CI 1.26-1.73), gonorrhoea (OR 1.35* Correspondence: Graham.Giles@cancervic.org.au
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unless otherwise stated.95% CI 1.05-1.83), and HPV (OR 1.39 95% CI 1.12-2.06)
[2]. Recently, large prospective sero-epidemiological stud-
ies examining the associations between seropositivity to
infectious agents and prostate cancer [3,4] have reported
only modest associations between positive serology and
prostate cancer.
There is also growing evidence of associations between
prostate cancer risk and variants in genes involved in
the response to infection and inflammation. Common
genetic variants of genes functionally linked to inflam-
mation and immunity such as COX-2 [5], RNASEL [6]
and TLR4 [7] have been associated with prostate cancer
risk suggesting that infection and host response to infec-
tion may be involved in its development.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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seroepidemiological cohort studies have reported only
modest associations between evidence of exposure to
common STIs and prostate cancer risk (T. vaginalis OR
1.43 95% CI 1.00-2.03) [3] or no association (HPV-33
OR 1.14, 95% CI 0.76-1.72; C. trachomatis OR 1.13, 95%
CI 0.65-1.96) [4]. It is likely that these studies would have
been limited by the biases inherent in the measures of
exposure applied. Serological methods to measure past
infection by organisms such as C. trachomatis, N. gonor-
rhoea and HPV may underestimate actual exposure due
to poor sensitivity. Kirnbauer et al. [8] demonstrated
that only 59% of those positive for HPV16 DNA at the
cervix produced a measureable serological response.
The low sensitivity of serological assays may be due to
the waning of antibody titres over time. In addition, the
time to seroconversion may be lengthy and those in-
fected may not seroconvert at all [9].
It has also been suggested that these studies may have
been prone to misclassification bias, due to the wide-
spread use of prostate specific antigen (PSA) testing as a
screening device for prostate cancer within the study
period. This may have led to the inclusion of subclinical
slow-growing prostatic neoplasms that diminished their
ability to detect meaningful associations between mea-
sures of exposure and clinically significant phenotypes.
Therefore, in the current environment with respect to
PSA screening, studies should incorporate subgroup
analysis into their design in order to discriminate factors
that may influence the aetiology or progression of clinic-
ally relevant tumours from indolent phenotypes [10].
We examined archival tissue from aggressive and non-
aggressive prostate cancer phenotypes and used semi-
quantitative molecular methods to seek evidence of
infection by common sexually transmitted or other or-
ganisms at the tissue level.
We hypothesised that the prevalence of DNA from C.
trachomatis, U. urealyticum, U. parvum, T. vaginalis,
M. genitalium, herpes simplex virus (HSV) 1 and 2,
BK virus, Xenotropic murine leukemia virus-related virus
(XMRV), and human papillomavirus (HPV), was the same
across tumour phenotypes (non-aggressive and aggressive
prostate cancer). We screened samples against a panel of
sexually transmitted and other infectious organisms to de-
termine prevalence according to tumour phenotype.
Methods
Cases were drawn from three existing prostate cancer
research projects, (1) the Melbourne Collaborative Co-
hort Study (MCCS) [11], a population-based prospective
cohort study, recruited over the period 1990–1994, (2)
the Risk Factors for Prostate Cancer Study (RFPCS) [12],
a population-based case control study and (3) the Early
Onset Prostate Cancer Study (EOPCS) [13], a populationbased case series of males diagnosed with prostate can-
cer aged ≤56 years of age. Approval for use of the sam-
ples arising from these studies was given by the Human
Research Ethics Committee of Cancer Council Victoria.
Specimens were selected on the basis of Gleason score
[14] determined by review of diagnostic haemotoxylin
and eosin stained slides by a single pathologist (JP). Ag-
gressive and non-aggressive tumours were compared.
Aggressive tumours were defined as Gleason score ≥7,
poorly-differentiated, including tumours staged at T4,
N + (lymph node positive), or M + (distant metastases)
regardless of their Gleason score or grade of differen-
tiation. Non-aggressive tumours were defined as well-
differentiated with a Gleason score ≤6.
We used archival prostate tissues resected from men
that had undergone either radical prostatectomy (RP) or
transurethral resection of the prostate (TURP) within the
period 1992–2005. A total of 221 formalin-fixed paraffin-
embedded tissue blocks (including unaffected adjacent tis-
sue when available) representing 128 histopathologically
confirmed prostate cancers comprising TURP and RP spe-
cimens were examined.
We processed formalin-fixed, paraffin-embedded radical
prostatectomy and TURP specimens using the sandwich
sectioning method [15]. To minimize cross-contamination
between the samples, gloves and the microtome blade
were changed and the microtome washed with histolene,
bleach, and 80% ethanol between each sample. Formalin-
fixed paraffin-embedded breast tissue was sectioned
between every four prostate tissue blocks to ensure no
carry-over of DNA. The outer three-micrometer sections
were stained with haematoxylin and eosin and validated
by a single pathologist to confirm the presence of cancer
and the initial histological diagnosis (AL). The four inner
seven-micrometer sections remained unstained and were
utilised for DNA extraction and molecular assays.
Sections selected for DNA extraction were deparaf-
finised with histolene and absolute ethanol and the tis-
sue pellet air-dried. Digestion of the tissue was achieved
by resuspending the pellet in 160 μL Tissue Lysis Buffer
(Roche, Australia) and 40 μL proteinase K (Roche,
Australia) and incubating overnight in a heat block at
37°C. A 200 μL volume of lysate was extracted using the
MagNA Pure LC instrument and MagNA Pure LC DNA
Isolation Kit I (Roche, Australia) with an elution volume
of 100 μL as per the manufacturer’s protocol.
Integrity of the DNA extracted from prostate tissue
was ascertained by amplification of a 268 bp region of the
human beta-globin gene as previously described [16].
We qualitatively screened samples for Chlamydia tra-
chomatis by the COBAS® TaqMan® CT Test, v2.0 (Roche,
Australia). Amplification and detection of HPV on all sam-
ples was carried out using the PapType High-Risk (HR)
HPV Detection and Genotyping kit (Genera Biosystems,
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sive cases were screened by DNA ELISA kit HPV SPF10,
version 1 (Labo Bio-medical Products BV, Rijswijk, The
Netherlands) according to the manufacturer’s instructions.
Published primers, probes and Real-Time PCR protocols
for Ureaplasma urealyticum [18], Ureaplasma parvum
[18], Mycoplasma genitalium [19], Trichomonas vaginalis
[20,21], Xenotropic Murine Retrovirus [22], BK virus [23]
AND HSV [24] were applied to the screening of samples
with minor modifications (Table 1). Assays to detect T.
vaginalis and HSV 1 and 2 were performed on the Light-
Cycler Carousel (Roche, Australia) and all other assays on
the LightCycler 480 (Roche, Australia).Table 1 Primers, probes and commercial kits used in this stud
Organism Target Primers and probe
C. trachomatis CT cryptic
plasmid
U. urealyticum ureB gene UUureF GATCACATTTCCACTTATTT
UUureR AAACGACGTCCATAAGCA
UUure2MGB AAACGAAGACAAAGAAC





















BK virus TAg BK-Hirsch-1 AGCAGGCAAGGGTTCTATT
BK-Hirsch-2 GAAGCAACAGCAGATTCTC
Probe HEXAAGACCCTAAAGACTT







PC04 CAACTTCATCCACGTTCACResults and discussion
Of the 221 samples, 195 (88.2%) produced a 268 bp pro-
duct of the human beta-globin gene in quality control
PCR testing and were deemed suitable for further ana-
lysis. Of these, 49 cases were classified as aggressive and
66 cases as non-aggressive. Of the 49 aggressive cases,
13 cases also had an adjacent normal tissue block. Of
the 66 non-aggressive cases, 38 had both a tumour and
normal block available.
Table 2 shows the prevalence of M. genitalium, U.
urealyticum, and HSV (7.8%, <1% and <1% respectively)
and that no difference in prevalence between aggressive
and non-aggressive phenotypes was observed. Herpesy for detection, quantification and genotyping
s (5′ to 3′) Product size References
206 bp COBAS ® TaqMan ®
CT test, v2.0, Roche
GAAACA 100 bp Mallard et al. [18]
ACTTTA
G AAGTG 99 bp Mallard et al. [18]
TTTG
AC
AGCAA 78 bp Jensen et al. [19]
TACCGTTGTTATC
GGT-MGB
140-150 bp Genera Biosystems Ltd








ACTAAAT 128 bp Hirsch et al. [23]
AACA
TCCCTCTGATCTACACCAGTTTBHQ1
102 bp Riley et al. [20],




AC 268 bp Resnick et al. [16]
C
Table 2 Identification of infectious organisms in archival prostate cancer tissue
Overall prevalence
Organism Aggressive cases Non-aggressive cases Tumour tissue “Normal” tissueb
n = 49 n = 66 n = 115 % n = 51 %
HSV 0 1 1 0.87 0 0
Mycoplasma genitalium 5 4 9 7.83 1 1.96
Ureaplasma urealyticum 1 0 1 0.87 0 0
Othera 0 0 0 0 0 0
P-values from Fisher exact test comparing the prevalence of each infectious organism between aggressive and non-aggressive samples and between tumour and
normal tissue samples are all greater than 0.18.
aOther includes U. parvum, T. vaginalis, C. trachomatis, BKV, HPV and XMRV.
bAdjacent tissue with no histological evidence of cancer.
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1/66 non-aggressive prostate cancer tissues and in none of
49 aggressive prostate cancer tissues. Mycoplasma genita-
lium DNA was detected in 4/66 (6.0%) non-aggressive,
5/49 (10.2%) aggressive and in one cancer-unaffected
tissue block of an aggressive case. Ureasplasma urealyti-
cum DNA was detected in none of the non-aggressive and
1/49 (2.0%) aggressive prostate cancer cases. Ureaplasma
parvum, T. vaginalis, C. trachomatis, BKV, XMRV or
HPV DNA was not detected in any prostate cancer tissue
screened in this study.
Our negative findings with respect to the presence of
viral DNA in formalin-fixed prostate cancer tissues are con-
sistent with those of Bergh et al. [25] who screened 352
formalin-fixed paraffin embedded tissues of benign pros-
tatic hyperplasia cases for evidence of HSV 1 and 2, BKV
or HPV infection and detected no viral DNA. In addition,
Martinez-Fierro and colleagues [26] reported a low and in-
significant prevalence of XMRV and BKV DNA in fresh
frozen prostate material but reported a positive association
between prostate cancer and HPV prevalence (OR 3.98,
95% CI 1.17-13.56, p = 0.027), in contrast to our study that
did not detect HPV DNA in any prostate sample.
One of the weaknesses of our study is the limited stat-
istical power to detect moderate differences in the preva-
lence of infectious organisms due to the low prevalence
we observed in all our samples. For example, for M.
genitalia, the most prevalent organism in our samples,
the statistical power to detect a four-fold higher preva-
lence in tumour tissue samples than in normal tissue
samples (i.e. 8% vs 2%) at a 0.05 level of statistical sig-
nificance was lower than 50%.
Conclusions
The methods we employed for this study were direct
and robust with respect to sensitivity and specificity for
the target organisms. We chose primers that generated
small amplimers (≤268 bp) to account for fragmentation
of the DNA extracted from formalin-fixed paraffin em-
bedded tissues. We conclude that it is unlikely that the
microorganisms which were included in the candidatepanel contributed to the development of prostate cancer in
our Australian sample of prostate cancers due to the low
prevalence or complete absence of detectable microbial
DNA in the tissue samples. Our study hypothesis and aims
assumed persistent infection with the candidate organisms
allowing for molecular detection in the FFPE material. We
cannot exclude the possibility of an initial infection leading
to oncogenic sequelae followed by clearance either by nat-
ural immunity or administration of antibiotics.
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